All the news Showing 10 of 26 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources France to provide universal access to hepatitis C treatment Keith Alcorn / 01 June 2016 France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide treatment to everyone with stage 2 fibrosis immediately, ... Cost of eliminating viral hepatitis needs to take into account social as well as medical burden of disease Keith Alcorn / 04 May 2016 Securing commitments from national governments to treat viral hepatitis, scale up prevention activities and aim for elimination of hepatitis B and C by 2030 will require a broad coalition of forces – ... Sofosbuvir/daclatasvir combination could be produced for $200 per cure Keith Alcorn / 14 December 2015 Month-by-month tracking of the prices paid in India for the chemicals used to make hepatitis C direct-acting antivirals shows that it is now possible to make and sell a combination of drugs ... United States faces biggest burden of hepatitis C treatment costs before 2020 Keith Alcorn / 11 December 2015 The cost of treating hepatitis C (HCV) is likely to decline dramatically over the next decade in the United States, not because of cuts in drug prices but because the population in ... Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows Keith Alcorn / 17 November 2015 Around one in six people with hepatitis C in four US states had their prescriptions for direct-acting antivirals refused by insurers, and almost half of Medicaid recipients were denied reimbursement in 2014 ... Retreat of international donors and neglect of national governments threatens harm reduction services Roger Pebody / 21 October 2015 The availability of needle and syringe programmes, opioid substitution therapy and other harm reduction services for people who inject drugs is getting even worse in many parts of the world, due to ... Cost of comprehensive global viral hepatitis prevention and treatment effort might peak at $11 billion in 2025 Keith Alcorn / 15 September 2015 Reaching the World Health Organization’s proposed targets for viral hepatitis control by 2030 could require global funding of $11 billion per year by 2025, Stefan Wiktor of the WHO Hepatitis Programme told ... Medicines Patent Pool looks at hepatitis C Keith Alcorn / 14 September 2015 Greg Perry, Executive Director of the Medicines Patent Pool, told delegates at the World Hepatitis Summit in Glasgow last week that the organisation was considering how it could act to speed up ... Hepatitis C treatment for people in prison may be highly cost-effective in England Keith Alcorn / 08 June 2015 Reducing the duration of direct-acting antiviral treatment for hepatitis C will make treatment for people in prison in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C ... HCV is a major reason for healthcare utilisation in the United States Michael Carter / 24 June 2014 People with hepatitis C virus (HCV) infection are significant users of healthcare services in the United States, according to research published in the online edition of Clinical Infectious Diseases. Between 2001 and 2010, ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive